AUTH/3823/9/23 – Complainant v GSK

Alleged promotion to the public and missing obligatory information from promotional posts on LinkedIn

  • Case number
    AUTH/3823/9/23
  • Complaint received
    18 September 2023
  • Completed
    20 November 2024
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case was in relation to GSK employees’ interaction with LinkedIn posts that referred to momelotinib being approved for treatment of myelofibrosis in the USA. The complaint was that these online interactions amounted to promotion of a prescription only medicine to the public in the UK, and that they did not include the required prescribing information nor black triangle.

The outcome under the 2021 Code was:

No Breach of Clause 12.1

Requirement to include up-to-date prescribing information

No Breach of Clause 12.10

Requirement to include the black triangle in promotional material

No Breach of Clause 26.1

Requirement not to advertise prescription only medicines to the public

This summary is not intended to be read in isolation.
For full details, please see the full case report below.